var data={"title":"Sodium glycerophosphate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium glycerophosphate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/578491?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-glycerophosphate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sodium glycerophosphate: Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=sodium-glycerophosphate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium glycerophosphate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605852\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Phosphate Injection Shortage and Import of Glycophos (Sodium Glycerophosphate Pentahydrate): Updated</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The U.S. Food and Drug Administration (FDA) continues to allow importation of Glycophos (sodium glycerophosphate pentahydrate) from a Fresenius Kabi plant in Norway to alleviate the phosphate injection shortage. Unlike other phosphate products available in the US, sodium glycerophosphate pentahydrate is an organic phosphate product and varies from other phosphate products in terms of concentration, dosing, and preservative content; use caution when switching between products.</p>\n        <p style=\"text-indent:0em;\">Refer to the following for additional information <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?utm_campaign=CDER%20New%201%2F10&utm_medium=email&utm_source=Eloqua&AI=Phosphate+Injection+Products&st=c&tab=tabs-4&panels=0&elqTrackId=5aaf35f7b1e84c46ba92f9c134bf6630&elq=fcf240516dda4ef99be7b4e4bc0c1e1d&elqaid=2018&elqat=1&elqCampaignId=1372&amp;token=taJ500Kz8N8r8fjKjzbE0fbd2XmTMYqVGz2Eesy0/vxwDnAHBmBUXLigK3QmuFQ7PP3RWEo3NxTwBxewiGGJvH/P6UMfMhdbwrZnnnpPdy6H60N86BVah/u6Dak1fOS1IEE+RFdbYSnnpfcda/+ShdUzeX6Rg1i3sG0CMuOhyMAiQ0I+EYU793MUVq0LeK2Q4DuWs9UF1GlBIIHxajXZ6hPITbCtmnzMT+x57fTFthvm2eupHCz9oaEn7jGD1CWPGztbN5L99y0A1tlNTgXZ6UXOx3Uc65/44G5y/AOftTbeW+x2elgQYovK52OCcq4MMpTTOI8VOoxA++apWdOZTusSxsUu+N8mr9kxg7vlmuI=&amp;TOPIC_ID=89687\" target=\"_blank\">https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?utm_campaign=CDER%20New%201%2F10&amp;utm_medium=email&amp;utm_source=Eloqua&amp;AI=Phosphate+Injection+Products&amp;st=c&amp;tab=tabs-4&amp;panels=0&amp;elqTrackId=5aaf35f7b1e84c46ba92f9c134bf6630&amp;elq=fcf240516dda4ef99be7b4e4bc0c1e1d&amp;elqaid=2018&amp;elqat=1&amp;elqCampaignId=1372</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26974432\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Glycophos</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20520507\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Electrolyte Supplement, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605884\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When converting from inorganic phosphate products (ie, sodium phosphate and potassium phosphate), maintain the same mmol amount of phosphate. Doses are listed as mmol of phosphate. Sodium glycerophosphate pentahydrate 306.1 mg = sodium glycerophosphate 216 mg = phosphate 1 <b>mmol</b>. Sodium glycerophosphate pentahydrate will provide 2 mEq of sodium for every 1 mmol of phosphate delivered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Phosphate replacement, parenteral nutrition: Manufacturer&rsquo;s labeling: IV: 10-20 mmol per day admixed within parenteral nutrition solution. Dosage should be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Phosphate repletion, general (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Caution: With orders for IV phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement.</b> The most reliable method of ordering IV phosphate is by millimoles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Acute treatment of hypophosphatemia:</b> IV: It is difficult to provide concrete guidelines for the treatment of severe hypophosphatemia because the extent of total body deficits and response to therapy are difficult to predict. Aggressive doses of phosphate may result in a transient serum elevation followed by redistribution into intracellular compartments or bone tissue. It is recommended that repletion of severe hypophosphatemia be done IV because large doses of oral phosphate may cause diarrhea and intestinal absorption may be unreliable. Intermittent IV infusion should be reserved for severe depletion situations; requires continuous cardiac monitoring. Guidelines differ based on degree of illness, need/use of TPN, and severity of hypophosphatemia. Obese patients and/or severe renal impairment were excluded from phosphate supplement trials. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown, 2006; Clark, 1995):</i> <b>Note:</b> Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing parenteral nutrition, do not exceed 15 mmol/L within parenteral nutrition. May use adjusted body weight for patients weighing &gt;130% of ideal body weight (and BMI &lt;40 kg/m<sup>2</sup>) by using [IBW + 0.25 (ABW-IBW)]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Low dose, serum phosphorus level 2.3-3 mg/dL (0.74-0.96 mmol/L): 0.16-0.32 mmol/kg over 4-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Intermediate dose, serum phosphorus level 1.6-2.2 mg/dL (0.51-0.71 mmol/L): 0.32-0.64 mmol/kg over 4-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">High dose, serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L): 0.64-1 mmol/kg over 8-12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Parenteral nutrition: </b> IV: 10-15 mmol/1000 kcal (Hicks, 2001) <b>or</b> 20-40 mmol/24 hours (Mirtallo, 2004 [ASPEN guidelines])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605883\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=sodium-glycerophosphate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sodium glycerophosphate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When converting from inorganic phosphate products (ie, sodium phosphate and potassium phosphate), maintain the same mmol amount of phosphate. Doses are listed as mmol of phosphate. Sodium glycerophosphate pentahydrate 306.1 mg = sodium glycerophosphate 216 mg = phosphate 1 <b>mmol</b>. Sodium glycerophosphate pentahydrate will provide 2 mEq of sodium for every 1 mmol of phosphate delivered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Phosphate replacement, parenteral nutrition: Manufacturer&rsquo;s labeling: IV: Infants: 1-1.5 mmol/kg per day admixed within parenteral nutrition solution. Dosage should be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Phosphate repletion, general (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Caution: With orders for IV phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement.</b> The most reliable method of ordering IV phosphate is by millimoles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Acute treatment of hypophosphatemia:</b> IV: It is difficult to provide concrete guidelines for the treatment of severe hypophosphatemia because the extent of total body deficits and response to therapy are difficult to predict. Aggressive doses of phosphate may result in a transient serum elevation followed by redistribution into intracellular compartments or bone tissue. It is recommended that repletion of severe hypophosphatemia be done IV because large doses of oral phosphate may cause diarrhea and intestinal absorption may be unreliable. Intermittent IV infusion should be reserved for severe depletion situations; requires continuous cardiac monitoring. Guidelines differ based on degree of illness, need/use of TPN, and severity of hypophosphatemia. Obese patients and/or severe renal impairment were excluded from phosphate supplement trials. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">There are no prospective studies of parenteral phosphate replacement in children. <b>The following weight-based guidelines for adult dosing may be cautiously employed in pediatric patients.</b> Guidelines differ based on degree of illness, use of TPN, and severity of hypophosphatemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>General replacement guidelines (Lentz, 1978):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Low dose, serum phosphorus losses are recent and uncomplicated: 0.08 mmol/kg over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Intermediate dose, serum phosphorus level 0.5-1 mg/dL (0.16-0.32 mmol/L): 0.16-0.24 mmol/kg over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">\n      <b>Note:</b> The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia, and lowered by 25% to 50% if the patient is hypercalcemic.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown, 2006; Clark, 1995):</i> <b>Note:</b> Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing parenteral nutrition, do not exceed 15 mmol/L within parenteral nutrition. May use adjusted body weight for patients weighing &gt;130% of ideal body weight (and BMI &lt;40 kg/m<sup>2</sup>) by using [IBW + 0.25 (ABW-IBW)]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Low dose, serum phosphorus level 2.3-3 mg/dL (0.74-0.96 mmol/L): 0.16-0.32 mmol/kg over 4-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Intermediate dose, serum phosphorus level 1.6-2.2 mg/dL (0.51-0.71 mmol/L): 0.32-0.64 mmol/kg over 4-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">High dose, serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L): 0.64-1 mmol/kg over 8-12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Parenteral nutrition: </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Infants and Children: 0.5-2 mmol/kg/24 hours (Mirtallo, 2004 [ASPEN guidelines])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Children &gt;50 kg and Adolescents: 10-40 mmol/24 hours (Mirtallo, 2004 [ASPEN guidelines])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605885\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605886\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling (has not been studied); use with caution since phosphate excretion is primarily renal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605887\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling (has not been studied); however, phosphate excretion is primarily renal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26974433\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glycophos: 1 mmol/mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26974431\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605894\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Must be diluted prior to parenteral administration. In general, the dose, concentration of infusion, and rate of administration may be dependent on patient condition and specific institution policy. For adult patients with severe symptomatic hypophosphatemia (ie, &lt;1.5 mg/dL), may administer at rates up to 15 mmol/hour (Charron, 2003; Rosen, 1995). In patients with renal dysfunction and/or less severe hypophosphatemia, slower administration rates (eg, over 4-6 hours) or oral repletion is recommended. Per the manufacturer, infusion time should not be &lt;8 hours and not &gt;24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20520467\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Supplement in intravenous nutrition to meet the requirements of phosphate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744913\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>General phosphate repletion during sodium phosphate and potassium phosphate shortages</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20603641\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">None reported by manufacturer. Adverse drug reactions listed have been reported in one small clinical trial (n=27); frequency may not be defined (Topp, 2011a). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Hypocalcemia (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20520468\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Patients in a state of dehydration or with hypernatremia, hyperphosphatemia, severe renal insufficiency, or shock</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605857\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte disturbances: Use with caution in patients with pre-existing electrolyte imbalances or risk of electrolyte disturbance (eg, hypocalcemia, hyperphosphatemia, hypernatremia). Use is contraindicated in patients who are dehydrated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Monitor closely for hyperphosphatemia, particularly when GFR is &le;20% of mean adult normal values (IOM, 1997). Use is contraindicated in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conversion from other phosphate products: Unlike phosphate products available in the U.S., sodium glycerophosphate pentahydrate is an organic phosphate product and varies from other phosphate products in terms of concentration, dosing, and preservative content; use caution when switching between products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616406\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616404\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89687&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605855\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Phosphorus requirements are similar in pregnant and nonpregnant women (IOM, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605856\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Phosphorus is a normal constituent of human milk (IOM, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605993\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum calcium, sodium and phosphorus levels; renal function; after IV phosphate repletion, repeat serum phosphorus level should be checked 2-4 hours later</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605992\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reference ranges may vary depending on the laboratory.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium: 8.4-10.2 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 4.5-7.5 mg/dL (1.45-2.42 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: ~4-6 mg/dL (1.29-1.94 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2.5-4.5 mg/dL (0.81-1.45 mmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605864\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Phosphorous participates in bone deposition, calcium metabolism, utilization of B complex vitamins, and as a buffer in acid-base equilibrium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20605866\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hydrolyzed to inorganic phosphate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Inorganic phosphate: 2.06 hours (Topp 2011a)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 4 hours (Topp 2011a)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Inorganic phosphate: Urine</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <b>Note:</b> One study involving 27 healthy volunteers compared pharmacokinetic data from infusions of 80 mmol sodium phosphate and 80 mmol sodium glycerophosphate pentahydrate delivered over a 4-hour period in a randomized, double-blind, crossover study. Bioequivalence was demonstrated between the two drugs in terms of serum AUC (0-24 hours) and C<sub>max</sub> levels of inorganic phosphate. However, the corrected excretion of inorganic phosphate in a 24-hour urine collection failed to demonstrate bioequivalence between sodium phosphate and sodium glycerophosphate pentahydrate. It is suggested that a small amount of unhydrolyzed sodium glycerophosphate in the urine, undetectable by the assay, is responsible for this discrepancy (Topp, 2011a).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Inorganic phosphate is released from the glycerophosphate molecule by hydrolysis. The maximum amount of glycerophosphate that can be hydrolyzed per day is dependent on serum alkaline phosphatase activity; use caution in patients with reduced alkaline phosphatase activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27265716\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Glycophos Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mmol/mL (20 mL): $15.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777355\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Glycophos (CH, CN, DK, ES, FI, GB, GR, HK, LT, LV, NL, NZ, PL, PT, RO, SE, SI, TH);</li>\n      <li>Glycophose (TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brown KA, Dickerson RN, Morgan LM, et al, &ldquo;A New Graduated Dosing Regimen for Phosphorus Replacement in Patients Receiving Nutrition Support,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2006, 30(3):209-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/16639067/pubmed\" target=\"_blank\" id=\"16639067\">16639067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charron T, Bernard F, Skrobik Y, et al, &ldquo;Intravenous Phosphate in the Intensive Care Unit: More Aggressive Repletion Regimens for Moderate and Severe Hypophosphatemia,&rdquo; <i>Intensive Care Med</i>, 2003, 29(8):1273-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/12845429/pubmed\" target=\"_blank\" id=\"12845429\">12845429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark CL, Sacks GS, Dickerson RN, et al, &ldquo;Treatment of Hypophosphatemia in Patients Receiving Specialized Nutrition Support Using a Graduated Dosing Scheme: Results from a Prospective Clinical Trial,&rdquo; <i>Crit Care Med</i>, 1995, 23(9):1504-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/7664552/pubmed\" target=\"_blank\" id=\"7664552\">7664552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</i>, National Academy of Sciences, Washington, DC, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lentz RD, Brown DM, and Kjellstrand CM, &ldquo;Treatment of Severe Hypophosphatemia,&rdquo; <i>Ann Intern Med</i>, 1978, 89(6):941-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/102230/pubmed\" target=\"_blank\" id=\"102230\">102230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosen GH, Boullata JI, O'Rangers EA, et al, &ldquo;Intravenous Phosphate Repletion Regimen for Critically Ill Patients With Moderate Hypophosphatemia,&rdquo; <i>Crit Care Med</i>, 1995, 23(7):1204-10. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/7600828/pubmed\" target=\"_blank\" id=\"7600828\">7600828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topp H, Hochfeld O, Bark S, et al, &quot;Glycerophosphate is Interchangeable With Inorganic Phosphate in Terms of Safety and Serum Pharmacokinetics,&quot; <i>Pharmacology</i>, 2011a, 88(3-4):193-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/21986180/pubmed\" target=\"_blank\" id=\"21986180\">21986180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topp H, Hochfeld O, Bark S, et al, &ldquo;Glycerophosphate Does Not Interact With Components of Parenteral Nutrition,&rdquo; <i>Pharmacology</i>, 2011b, 88(1-2):114-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-glycerophosphate-drug-information/abstract-text/21865768/pubmed\" target=\"_blank\" id=\"21865768\">21865768</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89687 Version 44.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F20605852\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26974432\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F20520507\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20605884\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F20605883\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F20605885\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20605886\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20605887\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26974433\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26974431\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20605894\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F20520467\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744913\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20603641\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20520468\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20605857\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F20616406\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F20616404\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20605855\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20605856\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20605993\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F20605992\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20605864\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20605866\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F27265716\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777355\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/89687|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-glycerophosphate-patient-drug-information\" class=\"drug drug_patient\">Sodium glycerophosphate: Patient drug information</a></li><li><a href=\"topic.htm?path=sodium-glycerophosphate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium glycerophosphate: Pediatric drug information</a></li></ul></div></div>","javascript":null}